Log In
BCIQ
Print this Print this
 

SBC-105

  Manage Alerts
Collapse Summary General Information
Company Alexion Pharmaceuticals Inc.
DescriptionRecombinant enzyme that replaces the mutated ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) enzyme and increases production of pyrophosphate
Molecular Target Ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1) (CD39)
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPreclinical
Standard Indication Cardiovascular (unspecified)
Indication DetailsTreat generalized infantile arterial calcification (GACI)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$8,788.4M

$4,473.5M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/23/2015

$8,788.4M

$4,473.5M

0

Get a free BioCentury trial today